Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;28(8):2255-2261.
doi: 10.1016/j.jstrokecerebrovasdis.2019.05.009. Epub 2019 May 29.

Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer

Abhinaba Chatterjee  1 , Alexander E Merkler  2 , Santosh B Murthy  2 , Jaclyn E Burch  3 , Monica L Chen  1 , Gino Gialdini  1 , Hooman Kamel  2 , Karla V Ballman  4 , Babak B Navi  5
Affiliations

Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer

Abhinaba Chatterjee et al. J Stroke Cerebrovasc Dis. 2019 Aug.

Abstract

Objective: We sought to characterize the US nationwide temporal trends in recanalization therapy utilization for ischemic stroke among patients with and without cancer.

Methods: We identified all acute ischemic stroke (AIS) hospitalizations in the National Inpatient Sample from January 1, 1998 to September 30, 2015. The primary exposure was solid or hematologic cancer. The primary outcome was use of intravenous thrombolysis. The secondary outcome was use of endovascular therapy (EVT).

Results: Among 9,508,804 AIS hospitalizations, 503,510 (5.3%) involved cancer patients. Intravenous thrombolysis use among ischemic stroke patients with cancer increased from .01% (95% confidence interval [CI], .00%-.02%) in 1998 to 4.91% (95% CI, 4.33%-5.48%) in 2015, whereas intravenous thrombolysis use among ischemic stroke patients without cancer increased from .02% (95% CI, .01%-.02%) in 1998 to 7.22% (95% CI, 6.98%-7.45%) in 2015. The demographic- and comorbidity-adjusted odds ratio/year of receiving intravenous thrombolysis was similar in patients with cancer (1.21; 95% CI, 1.20-1.23) versus those without (1.20; 95% CI, 1.19-1.21). EVT use among ischemic stroke patients with cancer increased from .05% (95% CI, .02%-.07%) in 2006 to 1.90% (95% CI, 1.49%-2.31%) in 2015, whereas EVT use among ischemic stroke patients without cancer increased from .09% (95% CI, .00%-.18%) in 2006 to 1.88% (95% CI, 1.68%-2.09%) in 2015.

Conclusions: Among 9.5 million AIS hospitalizations, patients with cancer received intravenous thrombolysis about two thirds as often as patients without cancer. This difference persisted over time despite increased utilization in both groups. EVT utilization was similar between cancer and non-cancer AIS patients.

Keywords: Cancer; endovascular therapy; ischemic stroke; oncology; recanalization therapy; thrombolysis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests

The authors declare that they have no conflict of interest.

Figures

Figure 1.
Figure 1.
A and B. Intravenous Thrombolysis Use Among Hospitalizations for Ischemic Stroke in the National Inpatient Sample, 1998–2015. A. Annual rates of intravenous thrombolysis use among hospitalizations for acute ischemic stroke in the National Inpatient Sample from 1998–2015. Data is stratified by the presence of comorbid cancer. The lighter shade sections of the curves denote 95% confidence intervals. B. Annual rates of intravenous thrombolysis use among hospitalizations for acute ischemic stroke in patients with cancer in the National Inpatient Sample from 1998–2015. Data is stratified by cancer type, including patients with non-metastatic hematologic cancers, non-metastatic solid cancers, and metastatic hematologic or solid cancers.
Figure 1.
Figure 1.
A and B. Intravenous Thrombolysis Use Among Hospitalizations for Ischemic Stroke in the National Inpatient Sample, 1998–2015. A. Annual rates of intravenous thrombolysis use among hospitalizations for acute ischemic stroke in the National Inpatient Sample from 1998–2015. Data is stratified by the presence of comorbid cancer. The lighter shade sections of the curves denote 95% confidence intervals. B. Annual rates of intravenous thrombolysis use among hospitalizations for acute ischemic stroke in patients with cancer in the National Inpatient Sample from 1998–2015. Data is stratified by cancer type, including patients with non-metastatic hematologic cancers, non-metastatic solid cancers, and metastatic hematologic or solid cancers.
Figure 2.
Figure 2.
A and B Endovascular Therapy Use Among Hospitalizations for Ischemic Stroke in the National Inpatient Sample, 2006–2015. A. Annual rates of endovascular therapy use among hospitalizations for acute ischemic stroke in the National Inpatient Sample from 2006–2015. Data is stratified by the presence of comorbid cancer. The lighter shade sections of the curves denote 95% confidence intervals. B. Annual rates of endovascular therapy use among hospitalizations for acute ischemic stroke in patients with cancer in the National Inpatient Sample from 2006–2015. Data is stratified by cancer type, including patients with non-metastatic hematologic cancers, non-metastatic solid cancers, and metastatic hematologic or solid cancers.
Figure 2.
Figure 2.
A and B Endovascular Therapy Use Among Hospitalizations for Ischemic Stroke in the National Inpatient Sample, 2006–2015. A. Annual rates of endovascular therapy use among hospitalizations for acute ischemic stroke in the National Inpatient Sample from 2006–2015. Data is stratified by the presence of comorbid cancer. The lighter shade sections of the curves denote 95% confidence intervals. B. Annual rates of endovascular therapy use among hospitalizations for acute ischemic stroke in patients with cancer in the National Inpatient Sample from 2006–2015. Data is stratified by cancer type, including patients with non-metastatic hematologic cancers, non-metastatic solid cancers, and metastatic hematologic or solid cancers.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Smith WS, Lev MH, English JD, et al. Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. Stroke 2009;40:3834–3840. - PMC - PubMed
    1. Jauch EC, Saver JL, Adams HP Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870–947. - PubMed
    1. National Institute of Neurological Disorders and Stroke rt-TPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587. - PubMed
    1. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20. - PubMed
    1. Yeo LL, Paliwal P, Teoh HL, et al. Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol 2013;70:353–358. - PubMed

MeSH terms

Substances